Blue Earth Therapeutics will begin an open-label, multicenter trial to evaluate a next-generation radiopharmaceutical for metastatic castration-resistant prostate cancer.
Poster at AACR highlights in vitro and in vivosynthetic lethality activity of rucaparib in multiple cancer cell types and PDX tumors that harbor genetic or epigenetic alterations in non-BRCA HRR genes.
Pluvicto is indicated for the treatment of adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who were previously administered other anticancer therapies.
Lisa Cordes, PharmD, BCACP, BCOP, oncology clinical pharmacy specialist at the National Institutes of Health, discusses treatment options and telehealth for prostate cancer care.
The KEYLYNK-010 trial was evaluating a combination of pembrolizumab (Keytruda) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer who progressed following chemotherapy and either abiraterone acetate (Zytiga) or enzalutamide (Xtandi).
Supplemental new drug application submitted to the FDA for the approval of darolutamide (Nubeqa) plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.
The drug combination reduced the risk of disease progression by 34% versus the standard of care in first-line metastatic castration-resistant prostate cancer, clinical trial results show.
The drug's novel molecular structure may result in fewer toxic adverse effects.
Darolutamide exerts its effects via competitive inhibition of androgen binding.
Xyosted is indicated for conditions associated with a deficiency or absence of endogenous testosterone.
The meta-analysis is the first-of-its-kind phase 3 randomized clinical trial with individual patient data.
The phase 3 ARASENS trial is the only study prospectively designed to evaluate an androgen receptor inhibitor combined with docetaxel and androgen deprivation therapy in this patient population.
Proof-of-contest is inexpensive and quantifies specific antigens from a drop of blood within minutes.
More medication options mean a greater chance for patients to survive and enjoy a better quality of life.
Regularly testing before and during chemotherapy can help physicians determine early on if treatment is working.
However, the trial failed to demonstrate that dose-escalated radiation therapy (RT) was superior to conventional RT.
Study does not show clinically significant improvements in overall survival but does show benefits in secondary endpoints, which included rates of distant metastases, deaths due to prostate cancer, and PSA failure.
The multi-institutional clinic trial also concluded that there was no negative impact to quality of life for these patients.
The rate of distant metastasis at 10 years was 29% for individuals whose scores demonstrated more aggressive disease compared with 13% for those who showed lower risk.
Study results show that annual screening can identify cases of prostate cancer up to 8 times as often in those with hereditary Lynch syndrome than in those who do not get the tests.
Exercise can complement other treatments for prostate cancer, including androgen deprivation therapy, which can lead to significant reduction in lean mass and an increase in fat mass.
New therapeutics for prostate cancer must continue to be assessed for comparative safety and efficacy, as well as accessibility for patients.
Fluciclovine F 18 (Axumin), which is a radioactive diagnostic agent for injection that can be used to detect recurring prostate cancer.
The PROpel phase 3 trial met the primary endpoints of radiographic progressing-free for men with metastatic castration-resistant prostate when treated with Olaparib, combined with abiraterone.
Ten quiz questions to assess your knowledge on common symptoms and treatments for prostate cancer.
